Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Enteric Coated Aspirin Clear all

Conditions: Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 28 Days and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Preeclampsia
Interventions: Aspirin; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions: single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets; Drug
Lead sponsor: Vectura, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 4
States / cities: Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more

Conditions: Heart Disease
Interventions: Aspirin; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Preeclampsia
Interventions: Aspirin 81 mg Enteric Coated Tab - 1 tablet, Aspirin 81 mg Enteric Coated Tab - 2 tablets; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 14 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Aspirin-Associated Gastric Ulcers
Interventions: PA32540; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Blood Clot, Trauma
Interventions: Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH); Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years and older
Enrollment: 12,424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: Tucson, Arizona • Miami, Florida • Indianapolis, Indiana + 16 more

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PL2200 Aspirin Capsules, Enteric-coated aspirin caplets; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Miami, Florida • Lenexa, Kansas • Cincinnati, Ohio

Conditions: Hypercholesterolemia, Flushing
Interventions: Apple pectin, Aspirin 325 mg, Placebo; Other · Drug
Lead sponsor: Patrick Moriarty, MD, FACP, FACC; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy
Interventions: aspirin, omeprazole; Drug
Lead sponsor: POZEN; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer
Interventions: Aspirin, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 74 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression, Frailty
Interventions: Not listed
Lead sponsor: Anne Murray; Other
Eligibility: 65 Years and older
Enrollment: 19,114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 22
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 18 more

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Cardiovascular Disease, Interventional Cardiology
Interventions: Aspirin, Placebo, ticagrelor; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Ulcer
Interventions: PA32540, EC-Aspirin 325 mg; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Platelet Aggregation Inhibitors
Interventions: Aspirin; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression
Interventions: 100 mg enteric-coated aspirin, Placebo; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 65 Years and older
Enrollment: 19,114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2024
U.S. locations: 33
States / cities: Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 26 more

Conditions: Healthy
Interventions: aspirin, omeprazole; Drug
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hairy Cell Leukemia
Interventions: Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Predictors of Aspirin Failure in Preeclampsia Prevention

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

Aspirin Responsiveness in Women at Risk for Cardiac Events

Aspirin (ASA) Therapy and Preeclampsia Prevention

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

PREVENTion of Clot in Orthopaedic Trauma

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

Alternative Options to Minimize Niacin-Induced Flushing

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

Effects of ASA on Prostate Tissue

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

Aspirin in Reducing Events in the Elderly

A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia